Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature.
about
Erythropoietin or darbepoetin for patients with cancerSupportive management of patients with brain tumors.The use of recombinant erythropoietin for the treatment of chemotherapy-induced anemia in patients with ovarian cancer does not affect progression-free or overall survival.Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus > or = 10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trialErythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes.Meta-analysis of epoetin beta and darbepoetin alfa treatment for chemotherapy-induced anemia and mortality: Individual patient data from Japanese randomized, placebo-controlled trials.Effect of erythropoiesis-stimulating agent policy decisions on off-label use in myelodysplastic syndromes.Clinical relevance and treatment of nonautoimmune anemia in chronic lymphocytic leukemia.Onco-nephrology: an appraisal of the cancer and chronic kidney disease links.Prevalence and management of anaemia in patients with non-myeloid cancer undergoing systemic therapy: a Spanish survey.Patterns of erythropoiesis-stimulating agent use among Medicare beneficiaries with myelodysplastic syndromes and consistency with clinical guidelines.Patterns of care in community-based oncology practices for anemia associated with myelosuppressive chemotherapy.Erythropoietic stimulating agents.Impact of erythropoiesis-stimulating agent prescribing at an Asian cancer center, after release of safety advisories.Erythropoiesis-stimulating agents for anemic patients with cancer.Cancer-related fatigue: a practical review.Erythropoiesis-stimulating agents in cancer patients: reflections on safety.Darbepoetin alfa in the treatment of anemia in cancer patients undergoing chemotherapy.Prognostic impact of the combination of erythropoiesis-stimulating agents to cancer treatment: literature review.Fighting insomnia and battling lethargy: the yin and yang of palliative care.Blood utilization and hemoglobin levels in cancer patients after label and coverage changes for erythropoiesis-stimulating agents.Trends in anemia treatment among patients with five non-myeloid malignancies treated with chemotherapy in a large integrated health care delivery system in California, 2000-2013.The Safety of Erythropoiesis-Stimulating Agents for the Treatment of Anemia Resulting from Chronic Kidney Disease.Interventions for cancer-related fatigue: a scoping review.Purification and Characterization of Recombinant Darbepoetin Alfa from Leishmania tarentolae.Role of hematopoietic growth factors as adjuncts in the treatment of chronic hepatitis C patients.Single versus double-unit transfusion policy in hematology.Assessing the effect of darbepoetin alfa on patient-reported fatigue in chemotherapy-induced anemia in four randomized, placebo-controlled clinical trials.Recombinant human erythropoietin beta therapy: an effective strategy to reduce transfusion requirement in children receiving anticancer treatment.Synchronization of administrations of chemotherapy and erythropoiesis-stimulating agents and frequency of associated healthcare visits.Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients.Outcomes and predicting response in anaemic chemotherapy patients treated with epoetin alfa. A multicentre, 4-month, open-label study in Australia and New Zealand.
P2860
Q24202335-22B01B9D-2BE8-4458-A3EC-41906905161EQ30444752-86D5291B-1105-4291-A879-9BB70DEF1479Q30453014-4EBA13A2-6896-4AE1-BB1C-374AC0D3859EQ33499897-816E77D6-5A9D-4AC9-9659-80CA8ADB1B53Q33630871-98FEA8C7-62B8-42A2-8020-978746C1FA31Q34554073-893C290E-72D7-48AB-9BFA-EBA8905726F3Q34624263-E8AA85C6-EC7C-4005-84B0-13CA962ACF85Q35114910-6CC96EBA-A291-4277-8500-2389931D2D82Q36801561-4E2F0577-DB0A-46A7-BA77-C03416724DE7Q36875147-97C1DEE6-4F19-4589-A044-F21373FEE3C5Q36960399-769E05DF-CE2C-413F-AD0F-6DE61D89E0EDQ37466470-B443E0A0-D9C3-4B15-81F3-B350C83152F6Q37693160-7413C86D-6DC0-413F-8491-E4D51370E9EBQ37775781-CEB15BD6-0FF5-4E76-A9F9-955E0B3036D8Q37810966-CFBF3DBB-2811-48DF-B947-19ADDA593D09Q37843136-BF61F3C3-B923-4CFD-839D-52495C596754Q37960528-E2E46035-D826-49E2-B674-1077FF6BAD36Q38056750-740389A1-1D98-4D5E-991A-C19FCA2DE03DQ38115153-1B98CD1F-5AEF-4E04-8E9E-52DA7911754EQ38188834-5CF2B697-2C82-4F0A-ADF1-2F335F19A6E4Q38235807-E9840D51-8E55-4F25-BDE0-D8DEDA53E2DDQ38409690-C549B6D9-90E2-4C94-84D5-3925BE8EF5C3Q38740871-5349D2D9-CC8D-4FDD-8C12-16DDA2B71F07Q38851597-9F40D1D6-ABB6-416C-85F5-F419304EEBFFQ39695661-A0B90D0E-3623-49C8-B4C4-454977E53E84Q41860936-00A86926-E528-4036-B15A-BF8205B610F5Q43224599-B4F6519F-15B0-42B0-BCCA-D499115E5499Q44901457-3D361887-85B2-4989-B9E3-BFB7D6A50D6BQ44921002-0DBEA466-7B27-4C7D-ADA6-C60D588AADC8Q45251537-ED0C7CFF-DF2A-4A94-A9C3-B8B17BE497A5Q46293619-8B0A39C6-A089-4B4D-8AD0-92F993F2D152Q50621981-01C7B5F4-DFB7-4121-97CB-3FB32D407799
P2860
Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Clinical benefits and risks as ...... atic review of the literature.
@ast
Clinical benefits and risks as ...... atic review of the literature.
@en
type
label
Clinical benefits and risks as ...... atic review of the literature.
@ast
Clinical benefits and risks as ...... atic review of the literature.
@en
prefLabel
Clinical benefits and risks as ...... atic review of the literature.
@ast
Clinical benefits and risks as ...... atic review of the literature.
@en
P2093
P1476
Clinical benefits and risks as ...... atic review of the literature.
@en
P2093
Brian Sercus
Christopher Seaman
David H Henry
I Elaine Allen
Lawrence T Goodnough
Susan D Ross
P304
P356
10.1016/J.CLINTHERA.2006.06.003
P577
2006-06-01T00:00:00Z